|
|
| Line 1: |
Line 1: |
| | | | |
| | ==Human folate receptor beta (FOLR2) in complex with antifolate pemetrexed== | | ==Human folate receptor beta (FOLR2) in complex with antifolate pemetrexed== |
| - | <StructureSection load='4kn2' size='340' side='right' caption='[[4kn2]], [[Resolution|resolution]] 2.60Å' scene=''> | + | <StructureSection load='4kn2' size='340' side='right'caption='[[4kn2]], [[Resolution|resolution]] 2.60Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4kn2]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4KN2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4KN2 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4kn2]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4KN2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4KN2 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=LYA:2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC+ACID'>LYA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=LYA:2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC+ACID'>LYA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4km6|4km6]], [[4km7|4km7]], [[4kmx|4kmx]], [[4kmy|4kmy]], [[4kmz|4kmz]], [[4kn0|4kn0]], [[4kn1|4kn1]]</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4kn2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4kn2 OCA], [https://pdbe.org/4kn2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4kn2 RCSB], [https://www.ebi.ac.uk/pdbsum/4kn2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4kn2 ProSAT]</span></td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">FOLR2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
| + | |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4kn2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4kn2 OCA], [http://pdbe.org/4kn2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4kn2 RCSB], [http://www.ebi.ac.uk/pdbsum/4kn2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4kn2 ProSAT]</span></td></tr> | + | |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/FOLR2_HUMAN FOLR2_HUMAN]] Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells. | + | [https://www.uniprot.org/uniprot/FOLR2_HUMAN FOLR2_HUMAN] Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells. |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 24: |
Line 22: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| - | [[Category: III, C E.Dann]] | + | [[Category: Large Structures]] |
| - | [[Category: Wibowo, A S]] | + | [[Category: Dann III CE]] |
| - | [[Category: 5-methyltetrahydrofolate]] | + | [[Category: Wibowo AS]] |
| - | [[Category: Antifolate]]
| + | |
| - | [[Category: Folate receptor]]
| + | |
| - | [[Category: Folate receptor beta]]
| + | |
| - | [[Category: Folate-conjugate]]
| + | |
| - | [[Category: Folate]]
| + | |
| - | [[Category: Folic acid]]
| + | |
| - | [[Category: Folr2]]
| + | |
| - | [[Category: Gpi-anchored protein on eukaryotic membrane]]
| + | |
| - | [[Category: Membrane protein]]
| + | |
| - | [[Category: Transport protein]]
| + | |
| Structural highlights
Function
FOLR2_HUMAN Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells.
Publication Abstract from PubMed
Antifolates, folate analogs that inhibit vitamin B9 (folic acid)-using cellular enzymes, have been used over several decades for the treatment of cancer and inflammatory diseases. Cellular uptake of the antifolates in clinical use occurs primarily via widely expressed facilitative membrane transporters. More recently, human folate receptors (FRs), high affinity receptors that transport folate via endocytosis, have been proposed as targets for the specific delivery of new classes of antifolates or folate conjugates to tumors or sites of inflammation. The development of specific, FR-targeted antifolates would be accelerated if additional biophysical data, particularly structural models of the receptors, were available. Here we describe six distinct crystallographic models that provide insight into biological trafficking of FRs and distinct binding modes of folate and antifolates to these receptors. From comparison of the structures, we delineate discrete structural conformations representative of key stages in the endocytic trafficking of FRs and propose models for pH-dependent conformational changes. Additionally, we describe the molecular details of human FR in complex with three clinically prevalent antifolates, pemetrexed (also Alimta), aminopterin, and methotrexate. On the whole, our data form the basis for rapid design and implementation of unique, FR-targeted, folate-based drugs for the treatment of cancer and inflammatory diseases.
Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition.,Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, Meng W, Ratnam M, Zhang F, Dann CE 3rd Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15180-8. doi:, 10.1073/pnas.1308827110. Epub 2013 Aug 9. PMID:23934049[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, Meng W, Ratnam M, Zhang F, Dann CE 3rd. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15180-8. doi:, 10.1073/pnas.1308827110. Epub 2013 Aug 9. PMID:23934049 doi:10.1073/pnas.1308827110
|
